Mass Spectrometric Analysis TRIZ Cases

Isotopic Cookson derivatization lets one mass spectrometric assay separately quantify 25OHD2 and 25OHD3 across multiplex samples.

Computational signal decomposition corrects distorted isobaric reporter-ion ratios in MS2, improving peptide quantitation without slower MS3 scans.

Computational signal decomposition separates peptide and interfering ion contributions to correct MS2 reporter-ion ratios without MS3.

Symmetrical IROA isotope peaks enable reproducible metabolite identification and quantitation across instruments and over time.

Standardized isotopic Matrix peaks correct instrument and chromatographic drift, enabling reproducible metabolite identification and quantitation.

Sequential LC-MS/MS with APCI improves distinction and simultaneous quantification of vitamin A, α-tocopherol, and combined β/γ-tocopherol.

Isotopic derivatization lets one mass spectrometry assay separately quantify 25-hydroxyvitamin D2 and D3 across multiplexed patient samples.

Breath VOC signatures improve non-invasive oesophagogastric cancer detection and help monitor treatment efficacy when endoscopy misses cases.

Liquid chromatography isolates estrone from body fluids for direct MS detection, cutting prep time while improving sensitivity for clinical labs.

A 14-metabolite body-fluid panel quantified by mass spectrometry improves NAFLD onset risk prediction beyond genetics alone.

Eight body-fluid metabolites measured by mass spectrometry improve non-invasive NAFLD identification accuracy while avoiding liver biopsy.

A multi-biomarker panel with regression modeling improves early lung cancer risk stratification beyond smoking-based CT screening criteria.

Protease-digested target peptides and stable isotope standards enable precise multiplexed quantification of mitochondrial protein signatures.

Fecal biomarker measurement replaces burdensome fasting and sugar alcohol tests to assess intestinal barrier function more reliably.

Predictable trioxane bond cleavage helps identify low-abundance trimeric protein cross-links and improve structural modeling in MSn analysis.

Biomarker-based risk scoring improves selection for CT lung cancer screening by raising detection accuracy without increasing false positives.

A 1040/1008 cm⁻¹ Raman band ratio in aldehyde-fixed lymphoblasts enables faster, lower-complexity detection of KMT2A-rearranged ALL.

Multiple HDL-associated proteins are measured by mass spectrometry or immunoassay to improve CVD risk scoring and cholesterol efflux assessment.

Adding a 5–20% organic solvent stabilizes low-level neurogranin peptides in blood and reduces degradation-driven analysis variation.

Chemical aziridination converts lipid C=C bonds into diagnostic products for accurate isomer identification and quantification by tandem mass spectrometry.

Voltage-controlled derivatization creates diagnostic ions in MS/MS, revealing lipid double-bond positions and sn-positions.

Blood biomarker panels enable objective TBI diagnosis and severity stratification without relying solely on radiation-exposing CT imaging.

Capture moieties bind biomarkers into separable particle complexes, reducing biotin interference and improving diagnostic accuracy.

SDS can suppress protein signals and force precipitation steps; an MPD/co-reagent process separates complexes for rapid mass spectrometry analysis.

A regression model combines blood biomarkers to identify 76% of future lung cancer cases versus 42% with USPSTF criteria, without increased false positives.

A 280–400 nm chromophore, permanent charge, and reactive group support sensitive LDI-MS labeling while reducing matrix background interference.

This case uses immobilized aptamers and magnesium-buffered, low-monovalent-ion conditions to reduce biofluid interference during Fc capture.

ApoC3, ApoA1, and SAA1/2 measurements support targeted CVD risk scoring and cholesterol efflux capacity assessment.

Measuring urinary 3′,4′-didehydro-3′-deoxycytidine detects lupus nephritis and supports prognosis assessment without renal biopsy.